Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.
Bio-Matrix Scientific Group, Inc., (BMXP) a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced that its chairman and CEO, David R. Koos, was the key speaker on Agoracom’s CEO Interview where he summarized the sale of BMXP’s wholly owned subsidiary and operating entity, Bio-Matrix Scientific Group, Inc., (BMSG Nevada) to Tasco Holdings International, Inc., (THII).
Koos also stated noted that the OTC Bulletin Board is viewed as offering the potential for greater access to institutional investors. “On the Bulletin Board, the company will be more transparent to potential institutional investors. We believe that institutional investors are important to the company, as they may be able to facilitate a more rapid implementation of the business model and potential future revenues streams.”
Koos also updated the status of BMSG Nevada’s new Stem Cell Cryogenic facility, “Currently, the processing laboratory is under construction and should, based on our current estimates, be completed by the end of August 2006. Once completed, the facility will undergo extensive testing. The Class 10,000 clean room labs should be completed by the end of August 2006. The company currently anticipates that if third party commitments the company has received remain on schedule, the company believes it will be ready for specimens in the first part of the 4th quarter of 2006.”
Source: Obesity, Fitness & Wellness Week and News RX.com
Tasco Holdings International:
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517
About Tasco Holdings Inc.
Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.
The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.
Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings.
Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.
Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.
�